Close Menu

NEW YORK – NanoString Technologies reported after the close of the market on Thursday that its first quarter revenues shrank 4 percent year over year.

For the three months ended March 31, total revenues were $26.6 million compared with $27.7 million in the prior-year period, exceeding the average Wall Street estimate of $25.4 million.

The firm reported product and service revenue of $24.5 million for the quarter, a 15 percent year-over-year growth from $21.4 in Q1 2019.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.